Proteome-wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis

New England Journal of Medicine

Volumn 370, Issue 5, 2014, Pages 433-443

  Van Bon, L ^a,b   Affandi, A J ^a,b   Broen, J ^a,b   Christmann, R B ^a   Marijnissen, R J ^b   Stawski, L ^a   Farina, G A ^a   Stifano, G ^a   Mathes, A L ^a   Cossu, M ^b,e   York, M ^a   Collins, C ^a   Wenink, M ^b   Huijbens, R ^b   Hesselstrand, R ^g   Saxne, T ^g   DiMarzio, M ^a   Wuttge, D ^g   Agarwal, S K ^h   Reveille, J D ^h   Assassi, S ^h   Mayes, M ^h   Deng, Y ^a   Drenth, J P H ^c   De Graaf, J ^c   Den Heijer, M ^c   Kallenberg, C G M ^d   Bijl, M ^d   Loof, A ^c   Van Den Berg, W B ^b   Joosten, L A B ^c   Smith, V ⁱ   De Keyser, F ⁱ   Scorza, R ^e   Lunardi, C ^f   Van Riel, P L C M ^c   Vonk, M ^c   Van Heerde, W ^c   Meller, S ^j   Homey, B ^j   Beretta, L ^e   Roest, M ^b   Trojanowska, M ^a   Lafyatis, R ^a   Radstake, T R D J ^a,b   more..

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f UNIVERSITY OF VERONA   (Italy)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

^j HEINRICH HEINE UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; CXCL4 CHEMOKINE; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; INTERLEUKIN 3 ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROTEIN ANTIBODY; PROTEOME; TACROLIMUS; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FLI1; UNCLASSIFIED DRUG; CYTOKINE; MESSENGER RNA; THROMBOCYTE FACTOR 4;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CELL ACTIVATION; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MARKER; DOWN REGULATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; LIVER FIBROSIS; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEOME WIDE ANALYSIS; PULMONARY HYPERTENSION; RISK ASSESSMENT; SKIN; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TRANSCRIPTOMICS; VALIDATION STUDY; ANIMAL; BLOOD; C57BL MOUSE; DENDRITIC CELL; METABOLISM; MIDDLE AGED; MOUSE; PATHOLOGY; SECRETION (PROCESS);

ADULT; ANIMALS; BIOLOGICAL MARKERS; CYTOKINES; DENDRITIC CELLS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; PLATELET FACTOR 4; PROTEOME; PULMONARY FIBROSIS; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SKIN;

EID: 84893081873     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1114576     Document Type: Article

References (39)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
2. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5. (Pubitemid 18073738)
3. Leroy EC. Connective tissue synthesis by scleroderma skin fibroblasts in cell culture. J Exp Med 1972;135:1351-62.
4. Lafyatis R, York M. Innate immunity and inflammation in systemic sclerosis. Curr Opin Rheumatol 2009;21:617-22.
5. Gu YS, Kong J, Cheema GS, Keen CL, Wick G, Gershwin ME. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008;38:132-60.
6. Gourh P, Agarwal SK, Divecha D, et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum 2009;60:3794-806.
7. Rueda B, Broen J, Simeon C, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet 2009;18:2071-7.
8. Radstake TR, Gorlova O, Rueda B, et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 2010;42:426-9.
9. Dieudé P, Guedj M, Wipff J, et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum 2009;60:225-33.
10. York MR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, Lafyatis R. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 2007;56:1010-20. [Erratum, Arthritis Rheum 2007;56:1675.] (Pubitemid 46399451)
11. Rönnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008;17:394-9. (Pubitemid 351798715)
12. Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci U S A 2006;103: 2770-5. [Erratum, Proc Natl Acad Sci U S A 2006;103:5242.]
13. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007;66:1008-14. (Pubitemid 47122311)
14. Eloranta ML, Franck-Larsson K, Lövgren T, et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 2010;69:1396-402.
15. Kim D, Peck A, Santer D, et al. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum 2008;58:2163-73. (Pubitemid 351988110)
16. Preliminary criteria for the classification of systemic sclerosis (scleroderma): subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
17. Holewijn S, den Heijer M, Swinkels DW, Stalenhoef AF, de Graaf J. The metabolic syndrome and its traits as risk factors for subclinical atherosclerosis. J Clin Endocrinol Metab 2009;94:2893-9.
18. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7. (Pubitemid 13221242)
19. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
20. van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S. Preliminary core sets for endpoints in ankylosing spondylitis. J Rheumatol 1997;24:2225-9. (Pubitemid 27474048)
21. Distler O, Rinkes B, Hohenleutner U, et al. Expression of RANTES in biopsies of skin and upper gastrointestinal tract from patients with systemic sclerosis. Rheumatol Int 1999;19:39-46. (Pubitemid 30025686)
22. Kahaleh MB, Osborn I, LeRoy EC. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med 1981;94:482-4. (Pubitemid 11103949)
23. Kodera M, Hasegawa M, Komura K, Yanaba K, Takehara K, Sato S. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum 2005;52:2889-96. (Pubitemid 41369120)
24. Antonelli A, Ferri C, Fallahi P, et al. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis - a longitudinal study. Rheumatology (Oxford) 2008;47:45-9. (Pubitemid 350286260)
25. Farina G, York M, Collins C, Lafyatis R. dsRNA activation of endothelin-1 and markers of vascular activation in endothelial cells and fibroblasts. Ann Rheum Dis 2011;70:544-50.
26. Rajkumar R, Konishi K, Richards TJ, et al. Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol 2010;298:H1235-H1248.
27. Rollins BJ. Chemokines. Blood 1997;90:909-28. (Pubitemid 27314123)
28. Aidoudi S, Bujakowska K, Kieffer N, Bikfalvi A. The CXC-chemokine CXCL4 interacts with integrins implicated in angiogenesis. PLoS One 2008;3(7):e2657.
29. Romagnani P, Maggi L, Mazzinghi B, et al. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J Allergy Clin Immunol 2005;116:1372-9. (Pubitemid 41740951)
30. Liu CY, Battaglia M, Lee SH, Sun QH, Aster RH, Visentin GP. Platelet factor 4 differentially modulates CD4+CD25+ (regulatory) versus CD4+CD25- (nonregulatory) T cells. J Immunol 2005;174:2680-6. (Pubitemid 40279682)
31. Radstake TR, van Bon L, Broen J, et al. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. PLoS One 2009;4(6):e5981.
32. Pitsilos S, Hunt J, Mohler ER, et al. Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost 2003;90:1112-20. (Pubitemid 38004432)
33. Zaldivar MM, Pauels K, von Hundelshausen P, et al. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology 2009;51:1345-53.
34. Asano Y, Stawski L, Hant F, et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 2010;176:1983-98.
35. Kubo M, Czuwara-Ladykowska J, Moussa O, et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003;163:571-81. (Pubitemid 36909419)
36. Farina G, Lafyatis D, Lemaire R, Lafyatis R. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2010;62:580-8.
37. Kowal-Bielecka O, Kowal K, Lewszuk A, Bodzenta-Lukaszyk A, Walecki J, Sierakowski S. Beta thromboglobulin and platelet factor 4 in bronchoalveolar lavage fluid of patients with systemic sclerosis. Ann Rheum Dis 2005;64:484-6. (Pubitemid 40283066)
38. Scheja A, Akesson A, Geborek P, et al. Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma). Arthritis Res 2001;3:178-82. (Pubitemid 32303434)
39. Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, Sato S. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol 2011;30:231-7.